Baseline clinicopathologic features on 3 therapeutic arms
| Characteristics | T-QB2450 (n = 23) | T-QB2450 + anlotinib 10 mg (n = 25) | T-QB2450 + anlotinib 12 mg (n = 27) | P value |
|---|---|---|---|---|
| Median age (range), y | 60 | 62 | 63 | |
| Gender, n (%) | 0.262 | |||
| Male | 21 (91.3) | 19 (76) | 20 (74) | |
| Female | 2 (8.7) | 6 (24) | 7 (26) | |
| Age group, n (%) | 0.328 | |||
| ≤ 60 y | 13 (56.5) | 9 (36) | 11 (41) | |
| > 60 y | 10 (43.5) | 16 (64) | 16 (59) | |
| Tobacco use history, n (%) | 0.938 | |||
| Never | 5 (21.7) | 7 (26) | 7 (26) | |
| Current | 3 (13.0) | 5 (19) | 3 (11) | |
| Previous | 12 (52.2) | 9 (33) | 13 (48) | |
| Unknown | 3 (13.0) | 4 (15) | 4 (15) | |
| Pathologic type, n (%) | 0.119 | |||
| Squamous cell carcinoma | 8 (34.8) | 7 (28) | 5 (19) | |
| Adenocarcinoma | 15 (65.2) | 14 (56) | 21 (77) | |
| Others | 0 (0) | 4 (16) | 1 (4) | |
| TNM stage, n (%) | 0.568 | |||
| IVA | 10 (43.5) | 10 (40) | 8 (30) | |
| IVB | 13 (56.5) | 15 (60) | 19 (70) |